Survival after surgery for spinal metastatic disease: a nationwide multiregistry cohort study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 34725074.
- Also identified by DOI 10.1136/bmjopen-2021-049198 and PMC identifier 8562515.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
To evaluate survival after surgery and indications for surgery due to spinal metastatic disease. A retrospective longitudinal multiregistry nationwide cohort study. 19 public hospitals in Sweden with spine surgery service, where 6 university hospitals account for over 90% of the cases. 1820 patients 18 years or older undergoing surgery due to spinal metastatic disease 2006-2018 and registered in Swespine, the Swedish national spine surgery registry. Decompressive and/or stabilising spine surgery due to spinal metastatic disease. Survival (median and mean) after surgery. Indications for surgery, types of surgery and causes of death. The median estimated survival after surgery was 6.2 months (95% CI: 5.6 to 6.8) and the mean estimated survival time was 12.2 months (95% CI: 11.4 to 13.1). Neurologic deficit was the most common indication for surgery and posterior stabilisation was performed in 70.5% of the cases. A neoplasm was stated as the main cause of death for 97% of the patients. Both median and mean survival times were well above the generally accepted thresholds for surgical treatment for spinal metastases, suggesting that patient selection for surgical treatment on a national level is adequate. Further research on quality of life after surgery and prognostication is needed.
Medical subject headings
- Quality of Life
- Spinal Neoplasms